ArticleMikrochimica acta2026
Aptamer modified magnetic nanoparticles for the determination of the allergenic protein α-lactalbumin in food samples.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamer-modified magnetic nanoparticles (Apt-MNPs) were synthetized and used as a magnetic solid-phase extraction (MSPE) sorbent for the selective isolation of α-lactalbumin (α-LA), an allergenic protein from cow’s milk. For this purpose, a thiol-terminated Apt was immobilized onto the surface of vinyl-functionalized MNPs via "thiol-ene" click chemistry reaction. The resulting Apt-modified MNPs were characterized and several parameters that affect the Apt-based MSPE efficiency were investigated. Under the optimal conditions, the developed Apt-based MSPE protocol was applied to the determination of α-LA in different foodstuffs (dairy-free products and those with declared milk content), yielding satisfactory recoveries (80.0–96.9%), good precision (RSD < 5.5%), and a low limit of detection (0.04 μg·mL⁻1). Moreover, the Apt-based sorbent proved to be highly affordable, with a cost of less than 4.2 € per sorbent, further supporting its suitability for routine analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.